Table 1.

Statistical table

Line	Data/dependent variable *	Type of test	Statistic	Confidence
a	15 min EBR ∼ 5 min EBR	Pearson's correlation	r = 0.98, dof =3	p = 0.002
b	Placebo: 1st half EBR ∼ 2nd half EBR	Pearson's correlation	r = 0.96, dof =18	p < 0.0001
c	Bromocriptine: 1st half EBR ∼ 2nd half EBR	Pearson's correlation	r = 0.84, dof =16	p < 0.0001
d	Placebo EBR	Dixon's test	Q = 0.30	p = 0.597
e	Bromocriptine EBR	Dixon's test	Q = 0.22	p = 0.908
f	Baseline EBR ∼ caudate BPND	Linear regression	t = −0.67, dof = 15	p = 0.512
g	Baseline EBR ∼ putamen BPND	Linear regression	t = −0.76, dof = 15	p = 0.461
h	Baseline EBR ∼ ventral striatum BPND	Linear regression	t = 0.95, dof = 15	p = 0.356
i	Baseline EBR ∼ midbrain BPND	Linear regression	t = 0.14, dof = 15	p = 0.890
j	Baseline EBR ∼ whole brain BPND	Linear regression	No significant cluster	p = 0.05 corrected for FWE
k	Baseline EBR, bromocriptine EBR	Pearson's correlation	r = 0.83, dof = 16	p < 0.0001
l	Baseline EBR, bromocriptine EBR	Paired t test	t = 0.35, dof = 17	p = 0.734
m	Changes in EBR ∼ body weight	Linear regression	t = −0.16, dof = 13	p = 0.877
n	Changes in EBR ∼ caudate BPND	Linear regression	t = −1.50, dof = 13	p = 0.157
o	Changes in EBR ∼ putamen BPND	Linear regression	t = −1.35, dof = 13	p = 0.199
p	Changes in EBR ∼ midbrain BPND	Linear regression	t = −0.11, dof = 13	p = 0.912
q	Changes in EBR ∼ ventral striatum BPND	Linear regression	t = −2.06, dof = 13	p = 0.060
r	Changes in EBR ∼ caudate BPND	Quadratic regression	t = −0.06, dof = 12	p = 0.951
s	Changes in EBR ∼ putamen BPND	Quadratic regression	t = 1.88, dof = 12	p = 0.085
t	Changes in EBR ∼ ventral striatum BPND	Quadratic regression	t = 1.18, dof = 12	p = 0.260
u	Changes in EBR ∼ midbrain BPND	Quadratic regression	t = 0.15, dof = 12	p = 0.882

^*age, sex, and time difference were covariates in all multiple regressions.